Ticker reaction data · Health Care

Eli Lilly (LLY)

LLY moved a median of +0.03% 30 minutes after news, and -0.07% by the close. How LLY actually reacts to news — the realized, point-in-time move the market made, measured across 2,000+ labeled events over the last three years with zero look-ahead.

The quantified answer

LLY’s median reaction, across the day.

+0.03%
Median 30-min
Typical reaction 30 minutes after any LLY news
52%
Moved up
Share of LLY news events that rose at 30 minutes
-0.07%
Median to close
Where LLY typically settles by the closing bell
LLY median reaction to newsLLY median reaction to news across 2 horizons: 30-min +0.03%, to close -0.07%.30-minto close30-min: +0.03%to close: -0.07%+0.03%-0.07%-0.07%0+0.03%
Median move vs. the price at the news timestamp, across 2,000+ labeled events.
Where LLY reactions landvs 2,000+ measured LLY reactions
LLYMiddle 50% · -0.57% to +0.60%Zero: 0.00%Median: +0.03%Median +0.03%-1.00%0+1.00%
Middle 50% of LLY reactions-0.57% to +0.60%
Median reaction (30-min)+0.03%
Measured reactions2,000+
Point-in-time · zero look-ahead

Half of all Eli Lilly news events land between -0.57% and +0.60% at 30 minutes.

Reaction stats as of 2026-07-14. Newest measured event . Reaction = percent move vs. the price at the news timestamp.

By event type

How LLY reacts, by analyst action.

EventEventsMedian 30-min% positiveMedian to close
Analyst upgrades45-0.13%47%-0.29%
Analyst downgrades32+0.12%56%-0.06%
Coverage initiations28+0.06%50%-0.83%
Rating reiterations243+0.01%53%-0.03%
Price-target raises100+0.07%57%+0.18%
Price-target cuts16+0.17%56%-0.23%

Last 3 years, pulled 2026-07-14. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how LLY ranks against every other measured name →

That’s how LLY usually reacts — get an email when it moves on news →
Next time, know first

Email me when LLY moves on news.

One email per qualifying move — the headline, the measured reaction, and how it compares to LLY's baseline. Nothing else.

▲ LLY Free · unsubscribe anytime
26M+ news records Operating since 2012 Methodology on SSRN ↗
Latest news

Recent LLY events, each with its measured reaction. (Page 1 of 8.)

DateHeadlineEventSource5-minTo close
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular diseasePress releasePR Newswire-0.65%-0.31%
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetesPress releasePR Newswire+0.59%-2.88%
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes studyPress releasePR Newswire-0.65%-0.31%
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitisPress releasePR Newswire+0.06%-2.48%
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparisonPress releasePR Newswire+0.34%+0.15%
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetesPress releasePR Newswire+0.06%-2.48%
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparisonPress releasePR Newswire+0.34%+0.15%
Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICsPress releasePR Newswire+0.69%+0.39%
FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areataPress releasePR Newswire+0.69%+0.39%
U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetesPress releasePR Newswire+0.80%+2.00%
Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020Press releasePR Newswire+0.33%+2.10%
U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancerPress releasePR Newswire+0.15%+0.66%
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic healthPress releasePR Newswire-0.26%-1.77%
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionsPress releasePR Newswire-0.12%-1.39%
Lilly to participate in Morgan Stanley 24th Annual Global Healthcare ConferencePress releasePR Newswire-0.01%-0.81%
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseasesPress releasePR Newswire-0.87%-1.13%
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesityPress releasePR Newswire-0.87%-1.13%
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetesPress releasePR Newswire-0.22%+0.32%
Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world studyPress releasePR Newswire-1.51%-3.33%
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black marketPress releasePR Newswire+0.17%+1.67%
Form 10-Q ELI LILLY & Co For: Jun 30SEC filing · Form 10-QSEC EDGAR+0.15%+0.96%
Form 8-K ELI LILLY & Co For: Aug 05SEC filing · Form 8-KSEC EDGAR+2.15%-1.59%
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progressPress releasePR Newswire+2.15%-1.59%
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancerPress releasePR Newswire-1.07%-2.66%
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1CPress releasePR Newswire+2.07%+3.84%
Lilly confirms date and conference call for second-quarter 2026 financial results announcementPress releasePR Newswire+0.01%+0.26%
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionsPress releasePR Newswire-0.78%+1.23%
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatmentPress releasePR Newswire+1.26%+0.44%
Lilly Canada receives long-awaited Ebglyss® CDA-AMC recommendation as well as pCPA LOI for atopic dermatitis (eczema)Press releaseCanada Newswire+0.56%+0.33%
Lilly launches "The Memory Radio Station" across Europe, inviting the public to visually reconstruct fading memories through GenAIPress releasePR Newswire+2.00%+7.03%
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapyPress releasePR Newswire+2.00%+7.03%
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight managementPress releasePR Newswire-1.35%-0.45%
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disordersPress releasePR Newswire-0.56%-1.56%
Form 11-K ELI LILLY & Co For: Dec 31SEC filing · Form 11-KSEC EDGAR+0.17%-0.02%
Lilly declares third-quarter 2026 dividendPress releasePR Newswire-0.25%+0.20%
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLLPress releasePR Newswire-1.68%-0.41%
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual MeetingPress releasePR Newswire-1.68%-0.41%
Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatablePress releasePR Newswire-0.29%-1.25%
Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non-communicable Disease and Chronic ConditionsPress releaseBusiness Wire+0.12%-1.57%
FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitisPress releasePR Newswire-0.29%-1.25%
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trialsPress releasePR Newswire-0.16%-0.81%
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopausePress releasePR Newswire-0.03%-0.81%
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complicationsPress releasePR Newswire-0.03%-0.81%
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual MeetingPress releasePR Newswire+0.98%-0.15%
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancerPress releasePR Newswire-0.93%-1.64%
Foundayo and Zepbound now covered for millions of AmericansPress releasePR Newswire+0.93%+2.62%
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity carePress releasePR Newswire-0.15%+0.04%
Lilly to participate in Goldman Sachs 47th Annual Global Healthcare ConferencePress releasePR Newswire-0.14%-0.46%
Lilly announces three acquisitions to build infectious disease portfolioPress releasePR Newswire-0.20%-1.00%
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemiaPress releasePR Newswire-0.20%-1.00%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Keep exploring

Where else LLY is measured.

LLY earnings → · Analyst actions → · SEC filings → · Full history →

Other Health Care names, measured the same way

TickerEventsMedian 30-min% positive
Johnson & Johnson (JNJ)2,000++0.06%56%
UnitedHealth Group (UNH)2,000+-0.03%48%

Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.

All Healthcare names, measured the same way →

Every ticker we measure the same way24
Method

How the numbers are made.

How is Eli Lilly's median reaction calculated?

Every labeled LLY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 2,000+ events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.

What counts as a positive reaction?

Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of LLY's measured events are up at 30 minutes; the rest close the window flat or negative.

How often is this page updated?

The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-07-14.

Does LLY's past reaction predict its next one?

No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.

Stop guessing what the event means

You just saw one reaction.
There are 26 million more.

For investors

Know the next move, measured.

Ticker alerts with the realized reaction — not the headline spin.

Free · no credit card · unsubscribe anytime
For builders

The dataset, one command away.

claude mcp add news-quantified

Then ask Claude: “how does LLY react to downgrades?” — or pull it raw via REST.

60-second signup on the NQ portal · 100 free credits/mo
26M+ news records, 2006–2026 Operating since 2012 Point-in-time, zero look-ahead Peer-reviewable methodology (SSRN) ↗